UNSPSC 51312607: Antazoline hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H19N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FP8Q8F72JH, chemically known as 2-(n-benzylanilino)methyl-2-imidazoline, hydrochloride but more generally known as antazoline hydrochloride, which bears US NIH Compound Identifier 17275. European Medicines Agency schedules Antazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00539MIG.

Most nations, for tariff and trade purposes, schedule antazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, ANTAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Antazoline hydrochloride bears US NLM identifiers UMLS ID C0282053 and NCI Concept Code C76668. SMILES: C1CCC(CC1)CN(CC2=NCCN2)C3CCCCC3.CL.

UNSPSC 51312607 Antazoline hydrochloride is a Commodity code that encompasses individual pharmaceutical products used in state and local health procurement, though recent solicitations tagged under this code show minimal direct purchasing of antazoline hydrochloride specifically. State and local governments buy pharmaceutical commodities under this tier through two primary channels: direct purchase agreements for specific medications supporting county health departments and community health initiatives, and multi-state cooperative purchasing vehicles that aggregate demand across state agencies and local government facilities. Issuing bodies include county health departments (such as Seminole County, Florida), state health and human services agencies (such as the Texas Health and Human Services Commission), and state-level cooperative purchasing alliances administered by state departments of administration. These entities procure generic pharmaceuticals, over-the-counter products, and specialty medications to support public health programs, emergency response, and community health initiatives.

Recent activity shows most solicitation volume concentrated in Florida and Minnesota, with secondary activity in Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs, though this represents exploratory information-gathering rather than a binding procurement.